Nautilus Biotechnology and Weill Cornell Medicine-Qatar Collaborate with The Michael J. Fox Foundation to Advance Single-Molecule Proteomics Research in Parkinson’s Disease

Rhea-AI Summary

Nautilus Biotechnology (NASDAQ: NAUT) announced a research collaboration with Weill Cornell Medicine-Qatar and The Michael J. Fox Foundation supported by a $1.6 million MJFF grant to develop a single-molecule assay measuring alpha-synuclein proteoforms for Parkinson’s disease biomarker research.

The project pairs Nautilus’ Iterative Mapping single-molecule proteomics platform with Lashuel lab expertise to probe post-translational modifications and enable improved disease detection, stratification, and monitoring.

News Market Reaction – NAUT

-7.62%

10 alerts

-7.62% News Effect

-3.8% Trough in 5 hr 52 min

-$22M Valuation Impact

$272M Market Cap

1.0x Rel. Volume

On the day this news was published, NAUT declined 7.62%, reflecting a notable negative market reaction. Argus tracked a trough of -3.8% from its starting point during tracking. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $22M from the company's valuation, bringing the market cap to $272M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Research grant: $1.6 million

1 metrics

Research grant $1.6 million MJFF grant supporting Parkinson’s single-molecule proteomics project

Market Reality Check

Price: $3.03 Vol: Volume 110,850 is 0.52x t...

low vol

$3.03 Last Close

Volume Volume 110,850 is 0.52x the 20-day average of 213,458, indicating lighter-than-normal trading activity. low

Technical Shares trade above the 200-day moving average of 1.14, reinforcing a constructive longer-term trend into this partnership news.

Peers on Argus

NAUT gained 9.85% while several peers also rose (e.g., CSBR +16.16%, QNCX +10.7%...

NAUT gained 9.85% while several peers also rose (e.g., CSBR +16.16%, QNCX +10.7%, EXOZ +3.69%, IPA +3.5%), but SEER declined -1.55%. With no peers in the momentum scanner and mixed moves, today’s action appears more company-specific than a broad sector rotation.

Historical Context

5 past events · Latest: Jan 08 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 08	Platform access launch	Positive	+0.0%	Early Access Program for tau proteoforms using single-molecule platform.
Nov 03	Field unit deployment	Positive	+39.1%	First external field evaluation unit shows reproducible tau proteoform data.
Oct 28	Q3 2025 earnings	Positive	+5.9%	Lower operating expenses, narrower loss, solid cash and pipeline progress.
Oct 07	Earnings date notice	Neutral	+0.1%	Announcement of upcoming Q3 2025 results and conference call timing.
Aug 27	Investor conferences	Neutral	-0.5%	Participation in September healthcare and investor conferences.

Pattern Detected

Operational and collaboration updates have often been followed by positive price reactions, while some platform-expansion news produced muted responses, suggesting selectivity in how investors reward milestones.

Recent Company History

Over the last six months, Nautilus has steadily advanced its single-molecule proteomics platform. A key milestone was the Buck Institute field evaluation unit, which produced highly reproducible data and coincided with a 39.1% move on Nov 3, 2025. Earnings on Oct 28, 2025 highlighted reduced operating expenses and a narrower loss, followed by a 5.93% gain. The January 2026 tau proteoforms early access launch continued this neurodegeneration focus. Today’s Parkinson’s collaboration extends that trajectory into alpha‑synuclein biomarker research.

Market Pulse Summary

The stock moved -7.6% in the session following this news. A negative reaction despite this collabora...

Analysis

The stock moved -7.6% in the session following this news. A negative reaction despite this collaborative grant-backed announcement would fit a pattern where not all scientific or strategic milestones translate into immediate shareholder enthusiasm. While the $1.6 million support from MJFF and alignment with leading academics advance the platform story, past news shows that market responses have been mixed across operational updates and conferences. Any sharp downside could also reflect profit-taking after prior gains or differing views on the timeline to meaningful commercialization.

Key Terms

single-molecule assay, proteomics, proteoforms, post-translational modifications, +4 more

8 terms

single-molecule assay technical

"Nautilus’ development of a single-molecule assay for measuring alpha-synuclein..."

A single-molecule assay is a laboratory test that can detect and measure individual molecules—such as a single protein, DNA strand, or virus particle—rather than averaging signals from many copies. Think of it like spotting one raindrop in a storm versus measuring total rainfall: it gives much earlier and more precise detection. For investors, this level of sensitivity can translate into breakthrough diagnostic products, smaller sample needs, faster time-to-result, and potential competitive advantage in medical testing and drug development markets.

proteomics medical

"current proteomics approaches are limited in their ability to measure specific..."

Proteomics is the large-scale study of all the proteins produced by a cell, tissue or organism, like taking a full inventory and watching how the workforce and machines inside a factory behave. For investors, proteomics matters because it helps identify drug targets, disease indicators and responses to treatments—information that can speed development, reduce risk, guide partnerships and reveal new commercial opportunities in biotech and diagnostics.

proteoforms medical

"platform for measuring proteins and their functional variants, called proteoforms..."

Proteoforms are the different molecular versions of a single protein that arise from small changes in its blueprint, how the blueprint is read, or chemical tweaks added after the protein is made. For investors, proteoforms matter because they can change how a drug, diagnostic test, or biologic performs and how reliably a biomarker signals disease—think of one basic cookie recipe producing many different cookies depending on mix-ins and decorations.

post-translational modifications medical

"post-translational modifications (PTMs) of the protein, including truncation..."

Chemical changes made to a protein after a cell builds it, acting like finishing touches that alter the protein’s shape, location, or activity. For investors, these changes matter because they control how biological targets behave, influence drug effectiveness and safety, affect biomarkers used to track diseases, and can change manufacturing or regulatory risk—similar to how tailoring can turn a basic garment into something that fits and functions differently.

biomarkers medical

"could serve as possible drivers of pathogenesis and biomarkers for diagnosis..."

Biomarkers are measurable indicators found in the body, such as substances in blood or tissues, that reveal information about health or disease. For investors, they can signal how well a medical treatment is working or whether a disease is developing, helping to assess the potential success or risks of healthcare companies or innovations. Think of biomarkers as biological signals that provide clues about a person’s health status.

tau proteins medical

"scale to disease targets including aSyn and tau proteins, the latter of which..."

Tau proteins are natural proteins inside brain cells that act like internal scaffolding and transport guides, helping maintain cell shape and move nutrients—imagine the wooden beams and tracks inside a house. They matter to investors because when tau proteins misfold and clump, they are linked to serious brain diseases and are a major focus for diagnostics, treatments and regulatory decisions; breakthroughs or setbacks in tau-targeting tests or drugs can strongly affect biotech valuations and trial outcomes.

affinity reagents technical

"protein standards and affinity reagents position the organizations to probe..."

Affinity reagents are specially designed molecules—such as antibodies, engineered proteins, or short strands of DNA/RNA—that stick tightly and specifically to a chosen biological target, like a protein or virus. For investors, they matter because they are the key component in diagnostic tests, research tools and some therapies; their quality, availability and intellectual property can directly affect a product’s accuracy, regulatory approval and commercial value, much like a custom key that enables a specific lock to work reliably.

neurodegenerative disease medical

"developing innovative assays...in health and neurodegenerative disease."

Neurodegenerative disease describes a group of progressive conditions in which nerve cells in the brain and spinal cord gradually lose function and die, leading to worsening symptoms such as memory loss, impaired movement, or changes in behavior—think of it like the wiring in a house slowly corroding and causing systems to fail. It matters to investors because these illnesses drive demand for long‑term care, diagnostics, therapies and medical devices, create large commercial and regulatory risks and opportunities, and can sharply affect company valuations when clinical trial results, approvals or setbacks are announced.

AI-generated analysis. Not financial advice.

• Support from The Michael J. Fox Foundation for Parkinson’s Research to advance critical research into Parkinson’s disease biology 
• Nautilus’ development of a single-molecule assay for measuring alpha-synuclein proteoforms is its latest application of Iterative Mapping method to uncover new biological insights
• Weill Cornell Medicine-Qatar’s deep chemical biology and neurology expertise and field-leading protein standards and affinity reagents position the organizations to probe disease-associated proteoforms at unprecedented resolution

SEATTLE and DOHA, Qatar, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering single-molecule proteome analysis; Weill Cornell Medicine-Qatar (WCM-Q); and The Michael J. Fox Foundation for Parkinson’s Research (MJFF) today announced a research collaboration to study the connection between the alpha-synuclein (aSyn) protein and Parkinson’s disease (PD). Supported by a $1.6 million research grant from MJFF, the high-impact project combines the Lashuel lab’s expertise in the molecular and chemical biology of neurodegeneration with Nautilus’ next-generation platform for measuring proteins and their functional variants, called proteoforms, at single-molecule resolution.

Understanding the many forms and modifications of alpha-synuclein is a key priority for MJFF, as these differences may improve our understanding of PD biology and variability across individuals. Through its discovery and biomarker research efforts, the Foundation supports innovative technologies to better characterize alpha-synuclein proteoforms and related pathways, with the aim of generating insights that can inform future clinical research. This work advances tools that strengthen biomarker development and, over time, help guide the design and outcomes of clinical trials.

Studies suggest that the protein aSyn may be a critical driver of PD pathogenesis and that post-translational modifications (PTMs) of the protein, including truncation and phosphorylation, could serve as possible drivers of pathogenesis and biomarkers for diagnosis. However, current proteomics approaches are limited in their ability to measure specific proteoforms of aSyn and how those proteoforms impact disease progression. To address this gap, collaborators at Nautilus, WCM-Q, and MJFF aim to develop a single-molecule assay to measure a large panel of aSyn proteoforms, thereby enabling new approaches to early detection, disease stratification, and disease monitoring for PD and related synucleinopathies.

Nautilus is pioneering a novel single-molecule platform and groundbreaking Iterative Mapping method with the potential to scale to disease targets including aSyn and tau proteins, the latter of which is initially validated and its real-world capabilities described in the company’s recent preprint.

“We are proud to receive a research grant from The Michael J. Fox Foundation for Parkinson’s Research and partner with the collaborative teams at MJFF and the Lashuel lab at Weill Cornell Medicine-Qatar to shed light on the underlying role of alpha-synuclein in Parkinson’s disease and to support efforts to advance biomarker research in Parkinson’s disease,” said Parag Mallick, Ph.D., co-founder and Chief Scientist of Nautilus. “This collaboration is further indication of the next-generation sensitivity, dynamic range, reproducibility, and versatility that our proteomics technology brings to neurodegenerative research and beyond.”

The lab of Hilal A. Lashuel, Ph.D., Professor of Neuroscience at WCM-Q is an internationally recognized leader in the research of aSyn and its role in PD, having studied its PTMs for decades, developed novel chemical-biology tools to develop proteoform standards, and developed a set of antibodies that target specific PTMs. The technologies created respectively by WCM-Q and Nautilus are expected to form the foundation of the aSyn proteoform assay.

“Deciphering alpha-synuclein proteoforms at the single-molecule level holds tremendous promise for advancing Parkinson’s disease diagnostics and therapies,” said Dr. Lashuel, who has published extensively on the importance of diverse forms of aSyn. “We are looking forward to working jointly with Nautilus and MJFF to realize this potential by developing innovative assays and technologies that will enable precise mapping of the post-translational modification signatures of alpha-synuclein in health and neurodegenerative disease.”

“At The Michael J. Fox Foundation, we support research that advances understanding of the biological mechanisms underlying Parkinson’s disease,” said Shalini Padmanabhan, PhD, Senior Vice President of Discovery and Translational Research at MJFF. “By investing in innovative approaches to study proteins such as alpha-synuclein, we aim to strengthen the foundation for future biomarker and therapeutic research through collaborations across academia and industry.”

About Nautilus Biotechnology, Inc.
With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio.

About Weill Cornell Medicine-Qatar
Weill Cornell Medicine-Qatar is a partnership between Cornell University and Qatar Foundation. It offers a comprehensive Six-Year Medical Program leading to the Cornell University M.D. degree with teaching by Cornell and Weill Cornell faculty and by physicians at Hamad Medical Corporation (HMC), Sidra Medicine, the Primary Health Care Corporation, and Aspetar Orthopedic and Sports Medicine Hospital, who hold Weill Cornell appointments. Through its biomedical research program, WCM-Q is building a sustainable research community in Qatar while advancing basic science and clinical research. Through its medical college, WCM-Q seeks to provide the finest education possible for medical students, to improve health care both now and for future generations, and to provide high quality health care to the Qatari population.

Many Weill Cornell Medicine physicians and scientists maintain relationships and collaborate with external organizations to foster scientific innovation and provide expert guidance. The institution makes these disclosures public to ensure transparency. For this information, see the profile for Dr. Lashuel; https://vivo.weill.cornell.edu/display/cwid-hil4001.

Special Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws. Forward-looking statements in this press release include, but are not limited to, statements regarding Nautilus’ expectations regarding the company’s expectations with respect to the potential of its platform technology, its future products, their functionality and performance or their applicability in biological research and in potentially enabling new diagnostics and therapies. These statements are based on numerous assumptions concerning the development of Nautilus’ products, target markets, and other current and emerging proteomics technologies, and involve substantial risks, uncertainties and other factors that may cause actual results to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that could materially affect the accuracy of Nautilus’ assumptions and its ability to achieve the forward-looking statements set forth in this press release include (without limitation) the following: Nautilus’ product platform is not yet commercially available and remains subject to scientific and technical development, which is inherently challenging and difficult to predict; we may experience material delays as a result of unanticipated events; we cannot provide any guarantee or assurance with respect to the outcome of our development, collaboration, and commercialization initiatives or with respect to their associated timelines. For a more detailed description of additional risks and uncertainties facing Nautilus and its development efforts, investors should refer to the information under the caption “Risk Factors” in our Annual Report on Form 10-K as well as in our Quarterly Report on Form 10-Q filed for the quarter ended September 30, 2025 and our other filings with the SEC. The forward-looking statements in this press release are as of the date of this press release. Except as otherwise required by applicable law, Nautilus disclaims any duty to update any forward-looking statements. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

Nautilus Media Contact
press@nautilus.bio

Nautilus Investor Contact
investorrelations@nautilus.bio

Weill Cornell Medicine-Qatar Media Contact
hyl2004@qatar-med.cornell.edu

FAQ

What did Nautilus (NAUT) announce on January 28, 2026 about Parkinson’s disease research?

Nautilus announced a collaboration with Weill Cornell Medicine-Qatar and MJFF to develop a single-molecule alpha-synuclein assay. According to Nautilus, the project is supported by a $1.6 million MJFF research grant to advance proteoform biomarker research for Parkinson’s disease.

How much funding did The Michael J. Fox Foundation provide to Nautilus (NAUT) for the aSyn study?

The Michael J. Fox Foundation provided a $1.6 million research grant for the project. According to Nautilus, the grant funds a collaboration to develop single-molecule assays measuring diverse alpha-synuclein proteoforms for biomarker and discovery work.

What is the goal of the Nautilus and Weill Cornell Medicine-Qatar collaboration on alpha-synuclein (NAUT)?

The goal is to develop a single-molecule assay to measure a broad panel of alpha-synuclein proteoforms. According to Nautilus, this aims to enable earlier detection, disease stratification, and improved monitoring tools for Parkinson’s disease and related synucleinopathies.

What technology will Nautilus (NAUT) use to measure alpha-synuclein proteoforms in the collaboration?

Nautilus will apply its single-molecule proteomics platform and Iterative Mapping method to detect proteoforms at single-molecule resolution. According to Nautilus, the approach builds on prior validation work, including real-world descriptions of tau capabilities in a recent preprint.

Why is Weill Cornell Medicine-Qatar’s Lashuel lab involved in the Nautilus (NAUT) project?

The Lashuel lab contributes decades of expertise studying alpha-synuclein post-translational modifications and proteoform standards. According to Nautilus, Lashuel’s chemical-biology tools and PTM-targeting antibodies will support assay development and precise proteoform mapping.

How could the Nautilus (NAUT) aSyn proteoform assay impact future Parkinson’s clinical research?

The assay could strengthen biomarker development and inform clinical trial design by characterizing proteoform signatures. According to Nautilus, insights from single-molecule proteoform measurements may guide future diagnostic and therapeutic research for Parkinson’s disease.